Nurix Therapeutics, Inc. Operating Income Loss

• Nurix Therapeutics, Inc. showed a decrease of -34.1% in Operating Income Loss from 2024 to 2025.
• This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Operating Income Loss has declined by 1,184.7%.
• Historical annual values: Fiscal year 2025: -$285.67 million | Fiscal year 2024: -$213.03 million | Fiscal year 2023: -$155.06 million | Fiscal year 2022: -$183.87 million | Fiscal year 2021: -$117.89 million | Fiscal year 2020: -$64.98 million | Fiscal year 2019: -$22.24 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026